Everolimus eluting stent vs first generation drug-eluting stent in primary angioplasty: A pooled patient-level meta-analysis of randomized trials

被引:51
作者
De Luca, Giuseppe [1 ]
Smits, Peter [2 ]
Hofma, Sjoerd H. [3 ]
Di Lorenzo, Emilio [4 ]
Vlachojannis, Georgios J. [2 ]
van't Hof, Arnoud W. J. [5 ]
van Boven, Ad J. [3 ]
Kedhi, Elvin [5 ]
Stone, Gregg W. [6 ]
Suryapranata, Harry [7 ]
机构
[1] Eastern Piedmont Univ, Div Cardiol, Osped Maggiore della Carita, Novara, Italy
[2] Maasstad Hosp, Div Cardiol, Rotterdam, Netherlands
[3] Leeuwarden Med Ctr, Div Cardiol, Leeuwarden, Netherlands
[4] SG Moscati, Div Cardiol, Avellino, Italy
[5] ISALA, Div Cardiol, Zwolle, Netherlands
[6] Columbia Univ, Med Ctr, Cardiovasc Res Fdn, New York, NY USA
[7] Radboud Univ Nijmegen Med Ctr, Dept Cardiol, Nijmegen, Netherlands
关键词
ELEVATION MYOCARDIAL-INFARCTION; BARE-METAL STENTS; PERCUTANEOUS CORONARY INTERVENTION; PATIENTS RISK PROFILE; 5-YEAR FOLLOW-UP; BIODEGRADABLE POLYMER; CLINICAL-IMPLICATIONS; BALLOON ANGIOPLASTY; REGRESSION ANALYSIS; REVASCULARIZATION;
D O I
10.1016/j.ijcard.2017.06.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Several concerns have emerged about the higher risk of very late stent thrombosis (ST) with first generation drug-eluting stent (DES) especially among STEMI patients. Newer generation DES has demonstrated to reduce ST at mid-term follow-up. Therefore, the aim of the present study is to performan individual patient's data meta-analysis of trials comparing 1st generation DES vs. 2nd generation DES (everolimus-eluting stent, EES) in patients undergoing primary percutaneous coronary intervention (PCI) for STEMI. Methods: We performed a formal search of electronic databases (MEDLINE and CENTRAL) and scientific session presentations from January 2010 to June 2016. We included all completed randomized trials comparing 1st vs. EES for patient presenting with STEMI. Results: Individual patients data were obtained from 3 trials, including a total of 1581 patients (686 or 43.4% randomized to 1st generation DES and 895 or 56.4% randomized to EES). At long-term follow-up (1584 +/- 588 days), EES did not significantly reduce mortality (7.8.% vs 11.7%, HR [95% CI]= 0.77 [0.52, 1.13], p= 0.18, p(heterogeneity) = 0.93), cardiac mortality (6.2% vs 7.6%, HR [95% CI] = 0.90 [0.56, 1.44], p = 0.65, p(heterogeneity) = 0.85), and reinfarction (8.1% versus 11.2%, respectively; HR [95% CI] = 0.74 [0.51, 1.07], p = 0.11, p(heterogeneity) = 0.52). However, EES significantly reduced the occurrence of ST (3.4% versus 6.1% respectively, HR [95% CI] = 0.56 [0.32, 0.97], p = 0.04, p(heterogeneity) = 0.42) and target vessel revascularization (TVR) (14.2% versus 20.1%; HR [95% CI]= 0.63 [0.42, 0.96], p = 0.03, p(heterogeneity) = 0.55). Landmark analysis showed more consistent benefits in ST with EES within 1 year, whereas benefits in TVR were mostly observed later than 1 year. Conclusions: The present pooled patient-levelmeta-analysis demonstrates that among STEMI patients undergoing primary PCI, EES as compared to 1st generationDES is associatedwith a significant reduction in ST and TVR at long-term follow-up. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:121 / 127
页数:7
相关论文
共 50 条
  • [21] Network meta-analysis of balloon angioplasty, nondrug metal stent, drug-eluting balloon, and drug-eluting stent for treatment of infrapopliteal artery occlusive disease
    Xiao, Yaowen
    Chen, Zhong
    Yang, Yaoguo
    Kou, Lei
    [J]. DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2016, 22 (05): : 436 - 443
  • [22] Safety and efficacy of everolimus-eluting stent versus zotarolimus-eluting stent: A meta-analysis of randomized controlled clinical trials and observational studies
    Gu, Hongqiu
    Hua, Kun
    Li, Wei
    Wang, Yang
    Yang, Jingan
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 201 : 552 - 560
  • [23] Comparison of outcomes after treatment of in-stent restenosis using newer generation drug-eluting stents versus drug-eluting balloon: Patient-level pooled analysis of Korean Multicenter in-Stent Restenosis Registry
    Lee, Joo Myung
    Rhee, Tae-Min
    Hahn, Joo-Yong
    Hwang, Doyeon
    Park, Jonghanne
    Park, Kyung Woo
    Kim, Hack-Lyoung
    Kim, Sang-Hyun
    Chae, In-Ho
    Doh, Joon-Hyung
    Jeon, Ki-Hyun
    Choi, Young Jin
    Park, Jin Sik
    Choi, Seung-Hyuck
    Gwon, Hyeon-Cheol
    Koo, Bon-Kwon
    Alfonso, Fernando
    Kim, Hyo-Soo
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 230 : 181 - 190
  • [24] XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent
    Beijk, Marcel A. M.
    Piek, Jon J.
    [J]. EXPERT REVIEW OF MEDICAL DEVICES, 2007, 4 (01) : 11 - 21
  • [25] Impact of drug-eluting stents with different coating strategies on stent thrombosis: A meta-analysis of 19 randomized trials
    Niu, Xiaowei
    Yang, Cuiling
    Chen, De
    He, Shengliang
    Yan, Dong
    Yao, Yali
    [J]. CARDIOLOGY JOURNAL, 2014, 21 (05) : 557 - 568
  • [26] Efficacy of Drug-Eluting Balloons for Patients With In-Stent Restenosis: A Meta-Analysis of 8 Randomized Controlled Trials
    Gao, Shen
    Shen, Jing
    Mukku, Venkata Kishore
    Wang, Mei Jia
    Akhtar, Muzina
    Liu, Wei
    [J]. ANGIOLOGY, 2016, 67 (07) : 612 - 621
  • [27] Comparison of the biodegradable polymer everolimus-eluting stent with contemporary drug-eluting stents: A systematic review and meta-analysis
    Picard, Fabien
    Pighi, Michele
    de Hemptinne, Quentin
    Airaksinen, Juhani
    Vinco, Giulia
    de Pommereau, Aurelien
    Biancari, Fausto
    Varenne, Olivier
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2019, 278 : 51 - 56
  • [28] Endovascular treatment of infrapopliteal arteries: angioplasty vs stent in the drug-eluting era
    Fanelli, Fabrizio
    Cannavale, Alessandro
    [J]. EUROPEAN RADIOLOGY, 2014, 24 (04) : 793 - 798
  • [29] Drug-Eluting Stents vs Intracoronary Brachytherapy for In-Stent Restenosis: A Meta-Analysis
    Lu, Yong-Guang
    Chen, Yan-Mei
    Li, Lang
    Zhao, Rong-Zhen
    Fu, Chun-Hui
    Yan, Hua
    [J]. CLINICAL CARDIOLOGY, 2011, 34 (06) : 344 - 351
  • [30] Drug-eluting Balloon Versus Second Generation Drug Eluting Stents in the Treatment of In-stent Restenosis: A Systematic Review and Meta-analysis
    Liou, Kevin
    Jepson, Nigel
    Cao, Chris
    Luo, Roger
    Pala, Sarvpreet
    Ooi, Sze-Yuan
    [J]. HEART LUNG AND CIRCULATION, 2016, 25 (12) : 1184 - 1194